ArticleTranslational lung cancer research2025
Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02705820 (A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy. (SWIPE)
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liquid biopsy, in the form of cell-free-DNA (cfDNA), circulating-tumour-DNA (ctDNA), and circulating tumour cells (CTCs) can be used to monitor the efficacy of systemic therapy. We investigated the predictive value of these markers in patients with advanced non-small cell lung cancer (aNSCLC) treated with pembrolizumab within a prospective phase-II maintenance study of pembrolizumab post-platinum-doublet-chemotherapy (NCT02705820). Methods: Plasma-derived cfDNA was evaluated in 125 patients' plasma samples at baseline (t0), after 3 weeks (t1), 6 weeks (t2) and 9 weeks (t3) from 46 individuals and analysed by next-generation sequencing to identify and quantify somatic mutations. CTCs were detected in peripheral blood mononuclear cells and characterised according to programme death-ligand 1 (PD-L1) and Ki67. Results: Patients presenting cfDNA increase at t2 had shorter progression-free survival (PFS; 2.05 Conclusions: Monitoring ctDNA mutation dynamics during early treatment could serve as a promising real-time predictor of response. Moreover, combining ctDNA-dynamics with Ki67 provides enhanced predictive accuracy for progression, supporting the importance of more holistic multifactorial analyses in the prediction of immunotherapy response in aNSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.